- Drugs List
- Therapeutic Indications
- Precautions and Warnings
- Pregnancy and Lactation
- Side Effects
Inhalation powder containing umeclidinium bromide.
Chronic obstructive pulmonary disease
One inhalation once daily, at the same time of day.
Maximum daily dose is one inhalation.
Children under 18 years
Precautions and Warnings
Benign prostatic hyperplasia
Bladder outflow obstruction
Glucose-galactose malabsorption syndrome
Narrow angle glaucoma
Severe cardiovascular disorder
Severe hepatic impairment
Ensure patient has a fast acting bronchodilator available
Check patient is using correct inhaler technique
Discontinue if paradoxical bronchospasm occurs
Advise patient not to use for relief of acute attacks
Advise patient to seek medical advice if treatment is ineffective
Use regularly to maintain freedom from symptoms
Pregnancy and Lactation
Use umeclidinium with caution during pregnancy.
The manufacturer recommends umeclidinium is not used in pregnancy unless the potential benefit to the mother outweighs the potential risk to the foetus. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity. At the time of writing there is limited human data available. Risks are unknown.
Umeclidinium is contraindicated during breastfeeding.
The manufacturer advises discontinuing breastfeeding or discontinuing umeclidinium. It is unknown whether umeclidinium is excreted in human milk. Effects on exposed infants are unknown.
Increased intra-ocular pressure
Upper respiratory tract infection
Urinary tract infections
It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.
The following number will direct the caller to the relevant local centre (0844) 892 0111
Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( www.toxbase.org ) or if this is unavailable at the backup site ( www.toxbasebackup.org ).
Last Full Review Date: December 2020
Summary of Product Characteristics: Incruse Ellipta 55 micrograms inhalation powder, pre-dispensed. GlaxoSmithKline (Ireland) Limited. Revised September 2019.
Already a member? Log in
Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content
FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.